The DUSP3 Knockout AGS Polyclonal Cells product comprises a heterogeneous population of human AGS gastric adenocarcinoma cells engineered using CRISPR/Cas9 technology to disrupt the DUSP3 gene. This polyclonal knockout pool is designed for research applications requiring loss-of-function analysis of dual-specificity phosphatase 3 (DUSP3) in a gastric cancer model system. The cells are provided as a pooled polyclonal population, maintaining genetic diversity while ensuring robust target-gene disruption across the culture, and are suitable for immediate use in a variety of cell-based assays.
The parental AGS cell line is a well-characterized human gastric adenocarcinoma line exhibiting epithelial morphology. Derived from a patient with gastric cancer, AGS cells serve as a standard in vitro model for investigating gastric tumor biology, including signal transduction, proliferation, and apoptosis. Their widespread use in oncology research makes them an appropriate host for evaluating the role of DUSP3 in MAPK signaling and gastric carcinogenesis.
DUSP3 encodes a dual-specificity phosphatase that dephosphorylates tyrosine and threonine residues on mitogen-activated protein kinases (MAPKs), primarily targeting ERK1/2 (MAPK3/MAPK1) but also interacting with p38 MAPK and JNK. By reversing phosphorylation events within the activation loop, DUSP3 functions as a critical negative regulator of the EGFR-RAS-RAF-MEK-ERK signaling cascade. Upstream stimuli such as epidermal growth factor (EGF) binding to EGFR, oxidative stress, and cellular stress promote MAPK activation, while DUSP3 transiently or constitutively counteracts this signaling to modulate downstream transcription factors including ELK1 and c-FOS. In the knockout context, loss of DUSP3-mediated dephosphorylation leads to sustained ERK1/2 activation, disrupting normal signal termination and altering gene expression programs governing cell cycle progression and apoptosis.
In AGS gastric adenocarcinoma cells, DUSP3 acts as a tumor-suppressive phosphatase by constraining MAPK pathway activity. Disruption of DUSP3 via CRISPR/Cas9 removes this regulatory checkpoint, resulting in hyperactivation of ERK signaling that can promote anchorage-independent growth, enhanced cell survival, and resistance to apoptotic stimuli. This model recapitulates features of gastric cancers with dysregulated MAPK signaling and provides a relevant platform for dissecting the contribution of phosphatase loss to tumor progression and therapeutic response.
Researchers can utilize this polyclonal knockout population to evaluate the biochemical and functional consequences of DUSP3 loss. Common experimental workflows include western blotting to assess phospho-ERK1/2 levels, RT-qPCR to confirm DUSP3 transcript absence, and co-immunoprecipitation to interrogate residual DUSP3 interactions with ERK2 or other MAPK partners. Cell viability and apoptosis assays, as well as colony formation assays, enable characterization of proliferative and survival phenotypes driven by sustained MAPK activation. Additionally, immunofluorescence studies can visualize ERK localization changes upon DUSP3 knockout. For further technical details or to place an inquiry, please contact Ascent Research.
